New combo shows promise in shrinking stomach tumors before surgery
NCT ID NCT04736485
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) helps shrink stomach cancer before surgery and prevent it from coming back. 67 adults with resectable stomach or gastroesophageal junction cancer received the combination before and after surgery. The main goal was to see how many patients had no cancer cells left in their tumor after the pre-surgery treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER BY AJCC V8 STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM Marseille
Marseille, France
-
APHP St Louis
Paris, France
-
CH St Malo
St-Malo, France
-
CHU Besançon
Besançon, France
-
CHU Poitiers
Poitiers, France
-
CHU Robert Debré
Reims, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, France
-
Centre Georges Francois Leclerc
Dijon, France
-
Chru Lille
Lille, France
-
ICO St Herblain
Saint-Herblain, France
-
Institut Mutualiste Montsouris
Paris, France
-
Institut Régional Cancer
Montpellier, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.